T-DM1 Approval Expanded to Include Some Women with Early-Stage HER2-Positive Breast Cancer


FDA has expanded the approved use of the drug ado-trastuzumab emtansine (Kadcyla), also called T-DM1, to include adjuvant treatment in some women with early-stage HER2-positive breast cancer.

Powered by WPeMatico